Lead Product(s) : Buparlisib,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AN2025 (buparlisib ) is an oral pan-PI3K inhibitor, It is being evaluated in combination with paclitaxel for the treatment of recurrent or metastatic head and neck squamous cell carcinoma.
Product Name : AN2025
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 17, 2023
Lead Product(s) : Buparlisib,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Buparlisib,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Cantor Fitzgerald
Deal Size : $106.1 million
Deal Type : Public Offering
Adlai Nortye Ltd. Announces Pricing of Initial Public Offering
Details : The net proceeds will fund the ongoing registrational trial for AN2025 (buparlisib), an oral pan-PI3K inhibitor that targets all class I PI3K isoforms, the milestone payments in connection with development of AN2025 and the commercial launch, if approved...
Product Name : AN2025
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 29, 2023
Lead Product(s) : Buparlisib,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Cantor Fitzgerald
Deal Size : $106.1 million
Deal Type : Public Offering
Lead Product(s) : Buparlisib,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Nucleai
Deal Size : Undisclosed
Deal Type : Partnership
Details : The collaboration aims to focus on identifying subjects that could derive benefit from AN2025 (buparlisib) treatment in metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) patients and will expand to other indications and clinical trials.
Product Name : AN2025
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 31, 2023
Lead Product(s) : Buparlisib,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Nucleai
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Buparlisib,Paclitaxel
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Cantor Fitzgerald
Deal Size : $57.5 million
Deal Type : Public Offering
Adlai Nortye Ltd. Announces Closing of Initial Public Offering
Details : The net proceeds will fund the ongoing registrational trial for AN2025 (buparlisib), an oral pan-PI3K inhibitor that targets all class I PI3K isoforms, the milestone payments in connection with development of AN2025 and the commercial launch, if approved...
Product Name : AN2025
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 10, 2023
Lead Product(s) : Buparlisib,Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Cantor Fitzgerald
Deal Size : $57.5 million
Deal Type : Public Offering